Trial Outcomes & Findings for Pegasys® in Patients With Myeloproliferative Diseases (NCT NCT00452023)
NCT ID: NCT00452023
Last Updated: 2024-12-11
Results Overview
CR = Reduction of PLT to \<440x109/l and disappearance of thromboembolic events, without the use of anagrelide or hydroxyurea PR = Reduction of PLT by 50% but still \>440x109/l or reduction of thromboembolic events by 50%, without the use of anagrelide or hydroxyurea
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
83 participants
Primary outcome timeframe
Up to 18 years
Results posted on
2024-12-11
Participant Flow
Participant milestones
| Measure |
IFN-alpha2a 450 Microgram (mcg) Injection
Starting dose 450 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 450 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 360 Microgram (mcg) Injection
Starting dose 360 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 360 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 270 Microgram (mcg) Injection
Starting dose 270 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 270 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 180 Microgram (mcg) Injection
Starting dose 180 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 180 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 90 Microgram (mcg) Injection
Starting dose 90 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 90 microgram (mcg) injection under the skin once a week
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
3
|
19
|
26
|
32
|
|
Overall Study
COMPLETED
|
3
|
3
|
19
|
26
|
32
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Pegasys® in Patients With Myeloproliferative Diseases
Baseline characteristics by cohort
| Measure |
IFN-alpha2a 450 Microgram (mcg)
n=3 Participants
Starting dose 450 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 450 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 360 Microgram (mcg)
n=3 Participants
Starting dose 360 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 360 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 270 Microgram (mcg)
n=19 Participants
Starting dose 270 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 270 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 180 Microgram (mcg)
n=26 Participants
Starting dose 180 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 180 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 90 Microgram (mcg)
n=32 Participants
Starting dose 90 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 90 microgram (mcg) injection under the skin once a week
|
Total
n=83 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
19 Participants
n=7 Participants
|
27 Participants
n=31 Participants
|
67 Participants
n=30 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
7 Participants
n=7 Participants
|
5 Participants
n=31 Participants
|
16 Participants
n=30 Participants
|
|
Age, Continuous
|
47 years
n=99 Participants
|
33 years
n=107 Participants
|
58 years
n=206 Participants
|
54 years
n=7 Participants
|
52 years
n=31 Participants
|
53 years
n=30 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
17 Participants
n=7 Participants
|
21 Participants
n=31 Participants
|
54 Participants
n=30 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
9 Participants
n=7 Participants
|
11 Participants
n=31 Participants
|
29 Participants
n=30 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
3 Participants
n=30 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
19 Participants
n=206 Participants
|
23 Participants
n=7 Participants
|
29 Participants
n=31 Participants
|
77 Participants
n=30 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
|
Region of Enrollment
United States
|
3 participants
n=99 Participants
|
3 participants
n=107 Participants
|
19 participants
n=206 Participants
|
26 participants
n=7 Participants
|
32 participants
n=31 Participants
|
83 participants
n=30 Participants
|
PRIMARY outcome
Timeframe: Up to 18 yearsCR = Reduction of PLT to \<440x109/l and disappearance of thromboembolic events, without the use of anagrelide or hydroxyurea PR = Reduction of PLT by 50% but still \>440x109/l or reduction of thromboembolic events by 50%, without the use of anagrelide or hydroxyurea
Outcome measures
| Measure |
IFN-alpha2a 450 Microgram (mcg)
n=3 Participants
Starting dose 450 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 450 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 360 Microgram (mcg)
n=3 Participants
Starting dose 360 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 360 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 270 Microgram (mcg)
n=19 Participants
Starting dose 270 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 270 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 180 Microgram (mcg)
n=26 Participants
Starting dose 180 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 180 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 90 Microgram (mcg)
n=32 Participants
Starting dose 90 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 90 microgram (mcg) injection under the skin once a week
|
|---|---|---|---|---|---|
|
Number of Patients With Complete Response (CR) or Partial Response (PR)
|
3 Participants
|
3 Participants
|
14 Participants
|
23 Participants
|
23 Participants
|
Adverse Events
IFN-alpha2a 450 Microgram (mcg)
Serious events: 1 serious events
Other events: 2 other events
Deaths: 0 deaths
IFN-alpha2a 360 Microgram (mcg)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
IFN-alpha2a 270 Microgram (mcg)
Serious events: 3 serious events
Other events: 9 other events
Deaths: 0 deaths
IFN-alpha2a 180 Microgram (mcg)
Serious events: 3 serious events
Other events: 8 other events
Deaths: 2 deaths
IFN-alpha2a 90 Microgram (mcg)
Serious events: 7 serious events
Other events: 7 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
IFN-alpha2a 450 Microgram (mcg)
n=3 participants at risk
Starting dose 450 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 450 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 360 Microgram (mcg)
n=3 participants at risk
Starting dose 360 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 360 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 270 Microgram (mcg)
n=19 participants at risk
Starting dose 270 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 270 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 180 Microgram (mcg)
n=26 participants at risk
Starting dose 180 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 180 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 90 Microgram (mcg)
n=32 participants at risk
Starting dose 90 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 90 microgram (mcg) injection under the skin once a week
|
|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Injury, poisoning and procedural complications
Ankle Fracture
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Cardiac disorders
Aortic Aneurism
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
carcinoma-facial
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Cardiac disorders
Cardiac Condition
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Surgical and medical procedures
Cardiac Surgery
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Injury, poisoning and procedural complications
Fatal Traffic Accident
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
General disorders
Fever
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Metabolism and nutrition disorders
Invasive adenocarcinoma of the colon
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Injury, poisoning and procedural complications
Leg wound
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 3 • Up to 18 years, one month and 23 days
|
|
Infections and infestations
Lung Infection
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Surgical and medical procedures
Surgery for post- menopausal bleeding
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Surgical and medical procedures
Resection of Small Intestine
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Nervous system disorders
Seizure
|
33.3%
1/3 • Number of events 4 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Vascular disorders
Vasculitis
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
Other adverse events
| Measure |
IFN-alpha2a 450 Microgram (mcg)
n=3 participants at risk
Starting dose 450 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 450 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 360 Microgram (mcg)
n=3 participants at risk
Starting dose 360 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 360 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 270 Microgram (mcg)
n=19 participants at risk
Starting dose 270 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 270 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 180 Microgram (mcg)
n=26 participants at risk
Starting dose 180 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 180 microgram (mcg) injection under the skin once a week
|
IFN-alpha2a 90 Microgram (mcg)
n=32 participants at risk
Starting dose 90 microgram (mcg) injection under the skin once a week.
IFN-alpha2a: Starting dose 90 microgram (mcg) injection under the skin once a week
|
|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
100.0%
3/3 • Number of events 3 • Up to 18 years, one month and 23 days
|
31.6%
6/19 • Number of events 6 • Up to 18 years, one month and 23 days
|
15.4%
4/26 • Number of events 4 • Up to 18 years, one month and 23 days
|
6.2%
2/32 • Number of events 2 • Up to 18 years, one month and 23 days
|
|
Investigations
Elevated transaminase
|
66.7%
2/3 • Number of events 2 • Up to 18 years, one month and 23 days
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 2 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
6.2%
2/32 • Number of events 2 • Up to 18 years, one month and 23 days
|
|
General disorders
Fatigue
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
General disorders
Pain
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Infections and infestations
Infection
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
6.2%
2/32 • Number of events 2 • Up to 18 years, one month and 23 days
|
|
Eye disorders
Blur Vision
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Nervous system disorders
Dizziness
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Gastrointestinal disorders
Mucositis
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
5.3%
1/19 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Skin and subcutaneous tissue disorders
Rash
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
3.8%
1/26 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
33.3%
1/3 • Number of events 1 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
0.00%
0/26 • Up to 18 years, one month and 23 days
|
3.1%
1/32 • Number of events 1 • Up to 18 years, one month and 23 days
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/3 • Up to 18 years, one month and 23 days
|
0.00%
0/19 • Up to 18 years, one month and 23 days
|
7.7%
2/26 • Number of events 2 • Up to 18 years, one month and 23 days
|
0.00%
0/32 • Up to 18 years, one month and 23 days
|
Additional Information
Lucia Masarova MD/Assistant Professor
The University of Texas MD Anderson Cancer Center
Phone: 832-750-4211
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place